New Drug: Aptensio XR (methylphenidate extended release)

Aptensio XR is a new long acting formulation of methylphenidate.   Methylphenidate in its immediate release form is, of course, Ritalin.    Long acting formulations include Concerta and Ritalin LA (both pills) and Quillivant XR (liquid).

Advantages:

• It  can be opened and sprinkled on food. 
• The release profile of Aptensio XR mostly earlier in the day, which may be of benefit to patients who have difficulty with sleep or appetite on Concerta.
• The release profile of Aptensio XR is more reliable than that of Ritalin LA.
• It is not less effective than other stimulants.

Disadvantages:

• Pill formulation means that titration may still be more difficult for patients who are more sensitive to medication.
• This is still a stimulant with all of the issues that stimulants bring including appetite suppression, insomnia, anxiety, and other, more uncommon problems.
• Like all new drugs, this one is likely to be expensive while it is still on patent.  The company is offering assistance to some patients via a copay assistance card  (see Aptensio XR website).  They will also help patients who require prior approval from their insurance company.

Reference:
"Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD." Welcome to Rhodes Pharmaceuticals. Rhodes Pharmaceuticals, LP, 21 May 2015. Web. 27 Oct. 2015.

Everything ADHD Medical Disclaimer

Everything ADHD Privacy Policy